MedTech Dive January 20, 2026
Penumbra is expected to give Boston Scientific more of a presence in the vascular surgery market, with little overlap between the two companies’ products.
Boston Scientific’s planned $14.5 billion acquisition of Penumbra started off the year with a bang. The two fast-growing, cardiovascular companies complement each other, with Boston Scientific seeing an opportunity to enter new markets, and Penumbra expecting its devices to gain a wider global reach.
Boston Scientific CEO Mike Mahoney explained how they reached a deal, saying there are few companies that can accelerate Boston Scientific’s growth, earnings per share and operating income margins.
“You have basically two companies that are strong independently, and in the combination have the potential to even become much stronger,” Mahoney...
Today's Sponsors
Today's Sponsor